Human Arterial Vasorelaxation
BPC-157 demonstrated endothelium-dependent nitric oxide-mediated vasorelaxation in human internal mammary artery samples.
[1]BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein originally isolated from human gastric juice. The molecule is stable in gastric acid, which is unusual for a peptide and supports both oral and injectable dosing. It has been studied extensively in preclinical models for tissue repair, gastrointestinal protection, and analgesia.
At a glance
- Type
- Synthetic pentadecapeptide (15 amino acids)
- Origin
- Derived from a protective protein originally isolated from human gastric juice
- Routes
- Oral and injectable (subcutaneous, intramuscular); stable in gastric acid
- Regulatory
- FDA 503A bulk substance interim do-not-compound list (2023); US compounding access restricted
- WADA
- Prohibited for competitive athletes
What the research supports
BPC-157 has the deepest preclinical evidence base of any unapproved peptide in the regenerative space, with hundreds of animal studies and recent human tissue validation.
Regeneration and Analgesia Review
Reviewed across tissue repair, GI mucosal protection, pain management, and emerging applications.
[2]Musculoskeletal Peptide Safety Review
Reviewed alongside other regenerative peptides for safety and efficacy in musculoskeletal injuries and athletic performance.
[3]Brain-Gut Axis and VEGF Pathway
Promotes angiogenesis via VEGF receptor and nitric oxide pathway modulation; modulates brain-gut axis and dopaminergic systems for pain control.
Summary of key findings
Deepest Preclinical Evidence
Hundreds of animal studies show consistent tissue repair effects across tendon, ligament, muscle, bone, and GI mucosa.
Oral and Injectable Routes
One of the few peptides documented stable on both routes due to gastric acid resistance.
Regulatory Restriction Since 2023
FDA placed BPC-157 on the 503A bulk substance interim do-not-compound list; US compounding access restricted.
WADA Banned
Prohibited for competitive athletes; testing consequences explicit.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
Protocols vary by route of administration and target tissue. Most cycles run 4 to 6 weeks with optional rest periods between cycles.
Protocol reference
| Protocol type | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Tendon, ligament, muscle repair | 250 to 500 mcg | SC near injury | Daily, often AM/PM split | 4 to 6 week cycles |
| GI mucosal repair | 500 mcg to 1 mg | Oral | Daily | Stable in gastric environment |
| Stacked tissue repair | 250 to 500 mcg | SC | Daily | Combines with TB-500 for tendon/muscle |
Intramuscular dosing: 250 to 500 mcg daily near the affected muscle or tendon.
Chronic injuries may extend protocols to 8 to 12 weeks.
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
BPC-157 has the deepest preclinical evidence base of any unapproved peptide in the regenerative space, with hundreds of animal studies showing consistent tissue repair effects. The major gap is human data; most published clinical work is small pilot trials and case series.
Recent 2026 human tissue work confirmed vasorelaxant activity in arterial samples through an endothelium-dependent nitric oxide pathway, providing mechanistic credibility. The 2023 FDA 503A interim do-not-compound listing changed the US regulatory landscape substantially; document carefully and verify pharmacy partner.
Pairs well with TB-500 for tendon and ligament work, with GHK-Cu for skin and connective tissue, and with growth hormone secretagogues for muscle recovery.
Tissue Repair
Tendon, ligament, muscle, bone, and GI mucosa across hundreds of animal studies.
GI Protection
Acid-stable oral route uniquely suited to gastrointestinal applications.
Analgesia
Brain-gut axis modulation for tissue-repair-associated pain.
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Yildirim et al., 2026 Endothelium-dependent vasorelaxation in human internal mammary artery
- 2Yuan et al., 2026 BPC-157 in tissue repair and pain management review
- 3Mendias and Awan, 2026 Peptide therapies for musculoskeletal injuries safety review
- 4Rahman et al., 2026 Therapeutic Peptides in Orthopaedics
- 5Mavrych et al., 2026 Therapeutic peptides in gerontology
Regulatory status, cautions and contraindications
FDA Regulatory Status
BPC-157 placed on the 503A bulk substance interim do-not-compound list in 2023. US compounding access is restricted. Document carefully and verify pharmacy partner.
WADA Prohibition
BPC-157 is banned for competitive athletes under WADA regulations. Testing consequences are explicit and enforceable.
Active Malignancy Caution
Theoretical caution due to pro-angiogenic activity. Use under strict medical supervision where any malignancy risk is present.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.